Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India''s Manufacturing Business

Ref: Akums/Exchange/2026-27/34 July 23, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition of Oriflame India’s Manufacturing business Respected Sir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of Akums Drugs and Pharmaceuticals Limited (“the Company”) at its Board Meeting held today, i.e. 23rd July, 2026 has, inter alia, considered and approved acquisition of Oriflame India Private Limited’s manufacturing business for total consideration of INR 56 Crore. It includes two manufacturing plants at Roorkee, Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse situated at Noida. Cosmetics is a fast-growing opportunity in India and this will mark as Akums’ entry into color cosmetics; and expand its presence in skincare & wellness products as well. The trademark and marketing of Oriflame’s products in India is not part of this transaction. The details required to be furnished under Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is annexed as “Annexure-A”. The above intimation was received by the Company today at 05:56 P.M. (IST) You are requested to kindly take the above information on your records. Thanking You Yours Faithfully For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As above Annexure-A Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: Sr. Particular Details a. Name of the target entity, details in brief such as size, Not applicable as no entity is being acquired. turnover etc. Further, Oriflame India Private Limited is in the business of manufacturing and marketing of cosmetic and wellness products. b. Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c. Industry to which the entity being acquired belongs Not Applicable, as no entity is being acquired. d. Objects and impact of acquisition (including but not The object is to acquire the manufacturing limited to, disclosure of reasons for acquisition of target business of Oriflame India Private Limited entity, if its business is outside the main line of business situated at two locations i.e. Roorkee, of the listed entity) Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse situated at Noida. This will expand Akums’ manufacturing capacity as well as capability of cosmetic and wellness products for Indian as well as global markets. e. Brief details of any governmental or regulatory No prior governmental or regulatory approvals approvals required for the acquisition are required to be obtained for the said transaction. f. Indicative time period for completion of the acquisition Acquisition is expected to be completed by 31st August 2026 g. Consideration - whether cash consideration or share Cash Consideration swap or any other form and details of the same h. Cost of acquisition and/or the price at which the For a total consideration of INR 56 Crores facilities are acquired i. Percentage of shareholding / control acquired and / or Not applicable number of shares acquired j. Brief background about the entity acquired in terms of Not applicable products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)